FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants respectfully request that Examiner return the initialed Form PTO 1449 that accompanied Applicants' Supplemental Information Disclosure Statement dated August 13, 2002.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following Reference Items 1-89 **(Exhibits 1-60)** which are listed again on the accompanying Form PTO 1449 **(Exhibit A)**. Applicants request that the Examiner review the publications and make them of record in the subject application.

Pursuant to the Notice appearing in the August 5, 2003 Official Gazette, because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. Patent Application Publications listed herein are not provided.

1. U.S. Patent No. 3,991,210, issued November 9, 1976 (Shea);

2. U.S. Patent No. 4,129,666, issued December 12, 1978 (Wizerkaniuk);

3. U.S. Patent No. 4,594,409, issued November 19, 1974 (Hayashi et al.);

4. U.S. Patent No. 5,965,600, issued October 12, 1999 (Sato, et al.);

5. U.S. Patent No. 6,024,981, issued February 15, 2000 (Khankari, et al.);

6. U.S. Patent No. 6,162,800, issued December 19, 2000 (Dolle, et al.);

7. U.S. Patent No. 6,362,161, issued March 26, 2002, (Konfino et al.);

8. U.S. Patent No. 6,514,938, issued February 4, 2003 (Gad et al.);

9. U.S. Patent No. 6,620,847, issued September 16, 2003 (Konfino, et al.);

10. U.S. Patent No. 6,800,285, issued October 5, 2004 (Yong and Chabot);

11. U.S. Patent No. 6,800,287, issued October 5, 2004 (Gad et al.);

12. U.S. Patent No. 6,844,314, issued January 18, 2005 (Eisenbach-Schwartz et al.);

13. U.S. Patent No. 6,939,539, issued September 6, 2005 (Konfino, et al.);

14. U.S. Patent No. 7,022,663, issued April 4, 2006 (Gilbert et al.);

15. U.S. Patent No. 7,033,582, issued April 25, 2006 (Yong, et al.);

16. U.S. Patent No. 7,074,580, issued July 22, 2006 (Gad et al.);

17. U.S. Patent Application Publication No. US-2002-0037848-A1, published March 28, 2002 (Eisenbach-Schwartz et al.);

18. U.S. Patent Application Publication No. US-2002-0055466, published May 9, 2002 (Aharoni et al.);

19. U.S. Patent Application Publication US-2002-0077278, published June 20, 2002 (Yong et al.);

20. U.S. Patent Application Publication No. US-2002-0107388-A1, published August 8, 2002 (Vandenbark);

21. U.S Patent Application Publication No. US-2003-0170729 A1, published September 11, 2003 (Klinger);

22. U.S Patent Application Publication No. US-2004-0006022 A1, published January 8, 2004 (Strominger, et al.);

23. U.S Patent Application Publication No. US-2005/0019322 A1, published January 27, 2005 (Rodriguez, et al.);

24. U.S. Patent Application Publication No. US-2005-0170004, published August 4, 2005 (Rosenberger);

25. U.S. Patent Application Publication No. US-2005-0171286, published August 4, 2005 (Konfino et al.);

26. U.S. Patent Application Publication No. US-2005-0256046, published November 17, 2005 (Gad et al.);

27. U.S. Patent Application Publication No. US-2006-0052586, published March 9, 2006 (Dolitzky);

28. U.S. Patent Application Publication No. US-2006-0122113, published June 8, 2006 (Pinchasi et al.);

29. U.S. Serial No. 10/543,764, filed July 18, 2005 (Aharoni et al.); **(Exhibit 1)**

30. U.S. Serial No. 10/547,463, filed August 30, 2005 (Pinchasi et al.); **(Exhibit 2)**

31. U.S. Serial No. 10/556,454, filed November 17, 2005 (Vollmer); **(Exhibit 3)**

32. U.S. Serial No. 10/577,588, filed April 27, 2006 (Rosenberger et al.); **(Exhibit 4)**

33. U.S. Serial No. 11/228,850, filed September 14, 2005 (Schwartz et al.); **(Exhibit 5)**

34. U.S. Serial No. 11/336,251, filed January 20, 2006 (Dolitzky); **(Exhibit 6)**

35. U.S. Serial No. 11/373,794, filed March 9, 2006 (Pinchasi); **(Exhibit 7)**

36. PCT International Application No. PCT/US00/14902 (WO 01/85797), published November 15, 2001 (Rodriguez, et al.); **(Exhibit 8)**

37. PCT International Application No. PCT/US01/19584, (WO 02/076503), published October 3, 2002; **(Exhibit 9)**

38. PCT International Application No. PCT/US02/38859 (WO 03/048735), published June 12, 2003 (Klinger); **(Exhibit 10)**

39. European Patent No. 0 378 246 A2, published June 18, 1990; **(Exhibit 11)**

40. European Patent No. EP 1 292 279, published March 19, 2003 (Yong et al.). Applicants point out that this reference is a counterpart of PCT International Application No. PCT/US01/18248 (WO 01/93828);

41. German Patent No. DE 3 930 733, issued March 28, 1991 (Vincze et al.) English-language abstract also being submitted; **(Exhibit 12)**

42. Russian Patent No. SU1690368, issued August 20, 1995 (Vlasov et al.) English-language abstract also being submitted; **(Exhibit 13)**

43. Russian Patent No. SU1469826, issued November 20, 1995 (Vlasov et al.) English-language abstract also being submitted; **(Exhibit 14)**

44. South African Patent No. 98/0214, issued September 29, 1999 (Arnon et al.). Applicants point out that this reference is corresponds to U.S. Patent No. 6,214,791; **(Exhibit 15)**

45. Soviet Union Patent No. SU1182051, issued September 30, 1985 (Khalikov et al.) English-language abstract also being submitted; **(Exhibit 16)**

46. Soviet Union Patent No. SU1664845, issued July 23, 1991 (Korn et al.) English-language abstract also being submitted; **(Exhibit 17)**

47. Aharoni, et al., "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", Proc. Natl. Acad. Sci. USA, 1997, 94, 10821-10826; **(Exhibit 18)**

48. Aharoni, et al., "Cop 1 Specific Supporessor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151", Neurology, 1997, Vol. 48, No. 3, A422; **(Exhibit 19)**

49. Aharoni, et al., "Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1", Journal of Neuroimmunology, 1998, 91, 135-146; **(Exhibit 20)**

50. Asakura et al., "A unique population of circulating autoantibodies promotes central nervous system remyelination", Multiple Sclerosis, 1998, 4, 217-221; **(Exhibit 21)**

51. Asakura et al., "Targeting of IgMk Antibodies to Oligodendrocytes Promotes CNS Remyelination", The Journal of Neuroscience, 1998, 18(19), 1700-1108; **(Exhibit 22)**

52. Batchelor, et al., Lancet, 1980 1(8178):1107-9; **(Exhibit 23)**

53. Bieber, et al., "Antibody-mediated remyelination: relevance to multiple sclerosis", Multiple Sclerosis, 2000, 6(2), S1-S5; **(Exhibit 24)**

54. Bieber, et al., "Humoral autoimmunity as a mediator of CNS repair", A Trends Guide to Neurodegenerative Disease and Repair/Review, 2001, 24(11), S39-S44; **(Exhibit 25)**

55. Bodanszky, M., "Principles of Peptide Synthesis," Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, 118-229; **(Exhibit 26)**

56. Bornstein, "Clinical Experience: Hopeful Prospects In Multiple Sclerosis, Hospital Practice, 1992, Vol. 27, No. 5, pp. 135-158; **(Exhibit 27)**

57. Duda, et al., "Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate", The Journal of Immunology, 2000, 165, 7300-7307; **(Exhibit 28)**

58. Fatma, et al., Swiss Med. Wkly, 2003, 133:541-543; **(Exhibit 29)**

59. Giuseppina, et al., The Journal of Clinical Investigation, April 2003, Vol. 111, No. 8, 1171-80; **(Exhibit 30)**

60. Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", Current Opin. Immunol., 2000, 12(6): 704-711; **(Exhibit 31)**

61. Johnson, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple

Sclerosis Study Group", Neurology, 45(7), 1268 (abstract); **(Exhibit 32)**

62. Kobayashi, et al., Clinical Exp. Immunology, 1990, June 80(3):400-3; **(Exhibit 33)**

63. Korczyn, et al., "Safety profile Of copolymer 1: Analysis Of Cumulative Experience In The United States And Israel", J. Neurol, 1996, Vol. 243 (Suppl. 1), S23-S26; **(Exhibit 34)**

64. Lombardi, et al., J. Invest. Dermatol., 1999 July 113(1):107-10; **(Exhibit 35)**

65. Lovell, K. and Jones, M., "CNS Infections, Spongiform Encephalopathy and Demyelinating Diseases," Karol Marcinkowski U. Med. Sci., Dept. Pathol., Poland, last updated on 2003-04-20, <URL:http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM>; **(Exhibit 36)**

66. Lymberi, et al., Arch. Hellen. Med., 16(4), July-August 1999, 337-351; **(Exhibit 37)**

67. McGavern, et al. "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?", The Neuroscientist, 1999, 5(1), 19-28; **(Exhibit 38)**

68. Merck Manual of Diagnosis and Therapy, Merck Research Laboratiories, Whitehouse Section, N.J., 17th Ed., 1999, 1300-1303, 1312-1317; **(Exhibit 39)**

69. Pavelko, et al., "Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination", The Journal of Neuroscience, 1998 18(7), 2498-2505; **(Exhibit 40)**

70. Pender, et al., Internal Med. Journal, 2002, 32: 554-563; **(Exhibit 41)**

71. Pharmacia Biotech Directory, 1996, pages 340-341; **(Exhibit 42)**

72. Physician's Desk Reference, 2000, Medical Economics Co. Inc., Montvale, NJ, 3115; **(Exhibit 43)**

73. Racadot, et al., "Treatment of Multiple Sclerosis With Anti-CD4 Monoclonal Antibody", J. of Autoimmunity, 1993, Vol. 6, pp. 771-786; **(Exhibit 44)**

74. Rodriguez, et al., "Immunoglobulins Reactive With Myelin Basic Protein Promote CNS Remyelination", Neurology, 1996, Vol. 46, pp. 538-545; **(Exhibit 45)**

75. Rodriguez, et al., "Neurological Therapeutics, 1998, 15(3): 245-250; **(Exhibit 46)**

76. Sela, M., et al., "Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases", Vaccine, 1992, Vol. 10, Issue 14, 991-999; **(Exhibit 47)**

77. Sridama, et al., Arch Intern Med., 1987, 147:229-231; **(Exhibit 48)**

78. Teva, et al., "Copolymer-1 Glatiramer Acetate Copaxone Agent for Multiple Sclerosis", Drugs of the Future, 1998, Vol. 23, No. 2, 213-214; **(Exhibit 49)**

79. Ure, et al., "Polyreactive Antibodies To Glatiramer Acetate Promote Myelin Repair In Murine Model Of Demyelinating Diseas", FASEB Journal, 2002, Vol. 16, pp. 1260-1262; **(Exhibit 50)**

80. Vandenbark, et al., "Specificity Of T Lymphocyte Lines For Peptide Of Myelin Basic Protein", The J. Of Immunology, 1985, Vol. 135, pp. 229-233; **(Exhibit 51)**

81. Van Noort, et al., International Review of Cytology, 1996, 178: 127-205; **(Exhibit 52)**

82. Wan, et al., Human Immunology, 2002, Apr. 63(4):301-10; **(Exhibit 53)**

83. Warrington, et al., "Immunoglobulin-mediated CNS repair", J. Allergy Clin. Immunol., 2001, S121-S125; **(Exhibit 54)**

84. Warrington, et al., "Human monoclonal antibodies reactive to oligodenrocytes promote remyelination in a model of multiple sclerosis", Neurobiology, 2000, 97(12), 6820-6825; **(Exhibit 55)**

85. Webster's II New Riverside University Dictionary, definition of "preventing", The Riverside Publishing Co., 1984, page 933; **(Exhibit 56)**

86. Weilbach, et al., "Disease Modifying Treatments For Multiple Sclerosis: What Is On The Horizon?" CNS Drugs, 1999, Vol. 11, No. 2, pp. 133-167; **(Exhibit 57)**

87. Wiesemann, et al., "Glatiramer Acetate (GA) induces IL-13/IL-5 secretion in naïve T cells", Journal of Neuroimmunology, 2001, 119, 137-144; **(Exhibit 58)**

88. Zhang, et al., "Murine Monoclonal Anti-Myelin Basic Protein (MBP) Antibodies Inhibit Proliferation And Cytotoxicity Of MBP-specific human T cell clones", J. of Neuroimmunology, 1989, Vol. 24, pp. 87-94; and **(Exhibit 59)**

89. "About Copaxone", Internet Article URL: http://www.mswatch.com/therapy/section.aspx?SectionId=789eabf5-3a07-4dff-a7ee-0d4ad138a6d. **(Exhibit 60)**

This Supplemental Information Disclosure Statement is being submitted after the mailing of the first Office Action but before the mailing date of a final Office Action. Under C.F.R. §1.97(c) and §1.17(p), the fee for filing an Information Disclosure Statement after the mailing of the first Office Action on the merits but prior to the mailing of a final Office Action is ONE HUNDRED EIGHTY DOLLARS ($180.00) and a check including this amount is enclosed. Accordingly, applicants request that this Fourth Supplemental Information Disclosure Statement be considered.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the $1,020.00 for three-month extension and $180.00 for information disclosure statement, is deemed necessary in connection with the filing of this Amendment. However, if any fee is deemed necessary, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Gary J. Gershik

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Gary J. Gershik 9/7/06
John P. White Date
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400